PDL BioPharma Inc

PDL BioPharma — Q2 2018 Earnings Presentation

12 slides from PDL BioPharma's earnings presentation, Aug 8, 2018

  1. Slide 1: Second Quarter 2018 Financial Results Conference Call

    PDL Second Quarter 2018 Financial Results Conference Call August 8, 2018

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements, including PDL's expectations with respectto its future royalty revenues, expenses, net income, and cash provided by operating activities. Each of these forward-looking statements involves risks and uncertainties. Actua

  3. Slide 3: Depomed Agreement — Before and After

    Depomed Agreement — Before and After o Original agreement: In October 2013, PDL paid $240.5 million for 100% of royalties and milestones on sales of type 2 diabetes products until cash flows reached $481 million or two times original investment, after which proceeds split evenly between PDL and Depo

  4. Slide 4: Cash Flows from Royalties 2018 to 2022

    Cash Flows from Royalties 2018 to 2022 Cumulative cash flows expected to exceed $400 million $120 $450 $400 $ 100 ss s3s0 = z = z sao 3300 & $ $250 = & seo s 2 $200 § Bag $150 2 g 2 & si00 § $20 $50 $s $ 2o1s 2019 2020 2021 2022 Year me Depomed ma U of M- Cordelga mam AceIRx mmm Vicogliosi Brothers

  5. Slide 5: Q2 Noden Impairment Results in a Book Value Decrease of $0.75 vs. Prior Quarter

    Q2 18 Noden Impairment Results in a Book Value Decrease of $0.75 vs. Prior Quarter $6.00 $5.75 $5.50 $5.25 $5.00 $4.75 $4.50 $4.25 $4.00 $3.75 $3.50 $3.25 $3.00 $2.75 $2.50 $2.25 $2.00 $1.75 $1.50 $1.25 $1.00 $0.75 $0.50 $0.2! $ PDL’s book value for the period ending June 30, 2018 was $4.85 Sep-13 P

  6. Slide 6: Noden Background

    Noden Background Q Noden Pharma = Platform upon which to build a pharmaceutical company. = PDL owns 100% of Noden companies. = Noden already has two products on the market—both indicated for hypertension. o Tekturna® and Tekturna HCT®, as they are known in the U.S., and Rasilez® and Rasilez HCT®, as

  7. Slide 7: Noden: Focus on Profitability

    Noden: Focus on Profitability a Reported revenues on the Noden products for Q218 of $25.9 million. = $10.4 million from US sales and $15.5 million from ROW. = 60 percent increase in productrevenues year over year. Q Noden sales successfully stabilized, discontinuing contract sales force and transiti

  8. Slide 8: LENSAR Evolution

    LENSAR Evolution ; ~li NaN \ AR NY, IF YOUR FEMTOSECOND CATARACT LASER HASN'T EVOLVED, IT’S PROBABLY EXTINCT Don't let your technology put you at risk for ‘extinction. Manage astigmatism with LENSAR®, now with Streamline? IV. Join the Evolution. [LEARN MORE>

  9. Slide 9: Second Quarter 2018 Financials

    Second Quarter 2018 Financials Three Months Ended Six Months Ended June 30, June 30, (In thousands, except per share amounts) 2018 2017 2018 2017 Royalties from Queen et al. patents S 1.218 $ 16.285 S$ 4,001 $ 30,441 Royalty rights - change in fair value 12,842 83.725 23,933 96,871 Interest revenue

  10. Slide 10: Second Quarter 2018 Financials

    Second Quarter 2018 Financials GAAP net income (oss) attributed to PDL's shareholders as reported Adjustments: Mark-to-market adjustment to fair value assets Non-cash interest revenues Non-cash stock-based compensation expense Non-cash debt offering costs Mark-to-market adjustment on warrants held I

  11. Slide 11: Second Quarter 2018 Financials

    Second Quarter 2018 Financials Condensed consolidated balance sheet (unaudited) June 30, December 31, 2018 2017 Cash, cash equivalents and investments $ 395,653 $ 532,114 Total notes receivable $ 70,887 $ 70,737 Royalty rights - at fair value $ 335,163 $ 349,223 Intangible assets, net $ 54,472 $ 215

  12. Slide 12: Question and Answer Session

    PDL Question and Answer Session

PDL BioPharma — Q2 2018 Earnings Presentation on 6ix